Medial Early Sign uses an artificial intelligence-based algorithm platform to help healthcare organizations optimize care and prevent or delay serious complications. The company is in the midst of developing a series of stratification products that it believes will detect various cancers, diabetes and other life-threatening conditions.
Here’s what you should know:
1. AMoon Fund was the lead investor, followed by Horizons Ventures and Nir Kalkstein, a co-founder of Medial EarlySign.
2. Company CEO Ori Geva said, “This funding will allow us to further broaden our suite of solutions, and expand clinical research and global implementations of our clinically-supported technology. The insights we enable could bring added value to almost every interaction with the patient, with the potential to positively impact millions of lives.”
3. The company’s products are being evaluated in ongoing clinical data studies taking place at more than 14 institutions around the world.
More articles on supply chain:
USPI driving growth for Tenet as hospital revenues shrink & more — 8 ASC company key notes
In defense of ASCs — key thoughts from ASCA CEO William Prentice
Nobilis to list on Canadian NEO Exchange: 4 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.